MX2022014007A - Compounds as bcl-2 inhibitors. - Google Patents

Compounds as bcl-2 inhibitors.

Info

Publication number
MX2022014007A
MX2022014007A MX2022014007A MX2022014007A MX2022014007A MX 2022014007 A MX2022014007 A MX 2022014007A MX 2022014007 A MX2022014007 A MX 2022014007A MX 2022014007 A MX2022014007 A MX 2022014007A MX 2022014007 A MX2022014007 A MX 2022014007A
Authority
MX
Mexico
Prior art keywords
inhibitors
bcl
compounds
methods
pharmaceutical compositions
Prior art date
Application number
MX2022014007A
Other languages
Spanish (es)
Inventor
Lijun Yang
Xingdong Zhao
Haohan Tan
Qihong Liu
Zhifu Li
Lihua Jiang
Zhifang Chen
Weibo Wang
Hongbin Liu
Ling Chen
Yue Rong
Rui Tan
Zuwen Zhou
Bin Liu
Weipeng Zhang
Chengxi He
Hua Xu
Shu Lin
Yunling Wang
Jinhua Yu
Original Assignee
Fochon Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fochon Pharmaceuticals Ltd filed Critical Fochon Pharmaceuticals Ltd
Publication of MX2022014007A publication Critical patent/MX2022014007A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
MX2022014007A 2020-05-08 2021-05-07 Compounds as bcl-2 inhibitors. MX2022014007A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063021816P 2020-05-08 2020-05-08
US202063115471P 2020-11-18 2020-11-18
US202163146601P 2021-02-06 2021-02-06
PCT/CN2021/092104 WO2021223736A1 (en) 2020-05-08 2021-05-07 Compounds as bcl-2 inhibitors

Publications (1)

Publication Number Publication Date
MX2022014007A true MX2022014007A (en) 2023-02-09

Family

ID=78468646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014007A MX2022014007A (en) 2020-05-08 2021-05-07 Compounds as bcl-2 inhibitors.

Country Status (11)

Country Link
US (1) US20230159527A1 (en)
EP (1) EP4146649A1 (en)
JP (1) JP2023525748A (en)
KR (1) KR20230051125A (en)
CN (1) CN115843297A (en)
AU (1) AU2021268845A1 (en)
BR (1) BR112022022608A2 (en)
CA (1) CA3177906A1 (en)
MX (1) MX2022014007A (en)
TW (1) TW202200576A (en)
WO (1) WO2021223736A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114478520A (en) * 2020-10-28 2022-05-13 杭州和正医药有限公司 Bcl-2 protein apoptosis inducer and application thereof
CN114681458B (en) * 2020-12-28 2023-07-18 苏州亚盛药业有限公司 Methods of treating multiple sclerosis
CN117616023A (en) * 2021-04-13 2024-02-27 爱新医药科技(香港)有限公司 BCL-2 or BCL-2/BCL-XL modulators and uses thereof
CA3238781A1 (en) * 2021-11-20 2022-11-10 Hongbin Liu Compounds as bcl-2 inhibitors
WO2023104043A1 (en) * 2021-12-06 2023-06-15 杭州和正医药有限公司 Anti-apoptotic protein bcl-2 inhibitor, pharmaceutical composition and uses thereof
WO2023231777A1 (en) * 2022-06-01 2023-12-07 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3459945A1 (en) * 2011-01-25 2019-03-27 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
CN106749233B (en) * 2016-11-24 2020-04-21 中山大学 Sulfonamide derivatives and application thereof
WO2019210828A1 (en) * 2018-04-29 2019-11-07 Beigene, Ltd. Bcl-2 INHIBITORS
US20220073513A1 (en) * 2018-12-29 2022-03-10 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
CN114929689B (en) * 2019-10-28 2024-08-27 百济神州有限公司 Bcl-2 inhibitors
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Also Published As

Publication number Publication date
TW202200576A (en) 2022-01-01
WO2021223736A1 (en) 2021-11-11
CA3177906A1 (en) 2021-11-11
JP2023525748A (en) 2023-06-19
US20230159527A1 (en) 2023-05-25
KR20230051125A (en) 2023-04-17
BR112022022608A2 (en) 2023-05-02
AU2021268845A1 (en) 2023-01-05
CN115843297A (en) 2023-03-24
EP4146649A1 (en) 2023-03-15

Similar Documents

Publication Publication Date Title
MX2022014007A (en) Compounds as bcl-2 inhibitors.
MX2022015272A (en) Inhibitors of kras g12c protein and uses thereof.
MX2022004304A (en) Apoptosis-inducing agents.
MX2021014441A (en) Tead inhibitors and uses thereof.
MX2021014443A (en) Tead inhibitors and uses thereof.
MX2022002465A (en) Kras g12d inhibitors.
MX2020007799A (en) Gcn2 inhibitors and uses thereof.
MX2018015892A (en) Boronic acid derivatives and therapeutic uses thereof.
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX2023008031A (en) Gcn2 inhibitors and uses thereof.
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
MX2020010116A (en) Macrocyclic compounds as trk kinases inhibitors.
WO2019035863A8 (en) Pyruvate kinase activators for use in treating blood disorders
MX2020009234A (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof.
MX2021001376A (en) Carboxamides as ubiquitin-specific protease inhibitors.
PH12019501639A1 (en) Jaki selective inhibitors
MX2022001004A (en) Enzyme inhibitors.
CR20220215A (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
CR20220216A (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
PH12020550608A1 (en) Pyrrole derivatives as acc inhibitors
MX2017013875A (en) Certain protein kinase inhibitor.
MX2023004869A (en) Antibodies against sars-cov-2 and uses thereof.
MX2023003443A (en) Alpha protein kinase 1 inhibitors and methods of use.
MX2022012239A (en) Amide compounds and uses thereof.
WO2022221528A3 (en) Kras g12c inhibitors